전립선암 방사선 치료 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트와 예측(2024-2032년)

Growth Factors of prostate cancer radiation therapeutics Market

The global prostate cancer radiation therapeutics market is entering a high-growth phase driven by rising prostate cancer incidence, increasing adoption of targeted radiopharmaceutical therapies, and expanding access to advanced oncology care worldwide. According to the latest market assessment, the global market was valued at USD 1.96 billion in 2024, is projected to grow significantly to USD 2.58 billion in 2025, and is expected to reach USD 15.19 billion by 2032, reflecting an exceptional CAGR of 28.8% (2025-2032). North America led the global landscape with 62.75% market share in 2024, supported by advanced healthcare infrastructure and robust reimbursement policies.

Market Overview and Key Growth Factors

Prostate cancer remains one of the most commonly diagnosed cancers in men, and the rising global patient pool continues to drive demand for effective treatment options. In 2022, the World Cancer Research Fund recorded 1,467,854 new prostate cancer cases worldwide, highlighting the urgent need for targeted therapies. Radiation therapeutics, especially the use of radioisotopes such as Radium-223 and Lutetium-177, are gaining rapid traction due to their superior precision. These treatments deliver radiation directly to cancer cells while minimizing damage to healthy tissue-a major advantage over conventional external beam radiation therapies.

Lutetium-177, in particular, dominates the market due to strong regulatory momentum and landmark product launches. Novartis' radioligand therapy Pluvicto (Lu-177) has set a new standard of care for prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (mCRPC), contributing significantly to the segment's expansion.

Drivers Strengthening Market Growth

A major driver fueling the growth trajectory is the rising geriatric population, as prostate cancer prevalence increases significantly with age. In 2023, the American Society of Clinical Oncology reported that 60% of prostate cancer cases occur in men over 65, highlighting the demographic shift influencing treatment demand.

Growing awareness programs and favorable reimbursement structures also promote early diagnosis and wider treatment adoption. Strong innovation pipelines, supported by major players like Bayer AG and Novartis AG, are advancing the availability of next-generation radiopharmaceutical therapies.

Market Restraints

Despite promising growth, high treatment costs remain a critical restraint. The development of radioisotopes and the specialized manufacturing required contribute to significantly high prices. For instance, the cost of a single vial of Pluvicto can reach approximately USD 50,856, posing accessibility challenges in low-income regions. Additionally, regulatory complexity and limited nuclear medicine infrastructure in emerging markets restrict broader adoption.

Opportunities and Emerging Trends

Growing collaborations among pharmaceutical companies and radioisotope manufacturers are creating new opportunities to support therapy expansion. In 2024, Ariceum Therapeutics partnered with Eckert & Ziegler for a global supply of isotopes such as Ac-225 and Lu-177, strengthening innovation pipelines.

A major emerging trend is the theranostics approach, which integrates diagnostic imaging with targeted therapy. This personalized treatment model enhances precision and improves survival outcomes. For example, Clarity Pharmaceuticals' SECuRE trial is advancing the development of 64Cu/67Cu-SAR-bisPSMA for metastatic castration-resistant prostate cancer, reflecting the industry's shift toward precision oncology.

Regional Outlook

North America, valued at USD 1.23 billion in 2024, remains the leading region due to a high prostate cancer burden, advanced nuclear medicine facilities, and significant R&D investment. The U.S. maintains dominance, supported by strong FDA activity, including the 2025 Fast Track Designation for Clarity Pharmaceuticals' 67Cu-SAR-bisPSMA.

Europe ranks second, driven by awareness movements like Movember and expanded access to targeted therapies.

Asia Pacific is the fastest-growing region (~33% CAGR), propelled by a rising elderly population and increasing prostate cancer diagnoses. Australia alone reported 26,400 new cases in 2024, accounting for 28% of total male cancer diagnoses.

Rest of the World markets such as the UAE are accelerating investments in precision medicine, evidenced by the 2024 launch of Burjeel Cancer Institute.

Competitive Landscape

The market is highly consolidated, with major players including Novartis AG, Bayer AG, Lantheus Holdings, Telix Pharmaceuticals, Ariceum Therapeutics, Radiopharm Theranostics, and Clarity Pharmaceuticals. Strategic collaborations, acquisitions, and regulatory approvals continue to shape the competitive environment, boosting innovation and treatment accessibility globally.

Segmentation By Radioisotope, Type, End-User, and Region

By Radioisotope * Radium-223

• Lutetium-177
• Others

By Type * Metastatic Castration-Resistant Prostate Cancer

• Non-Metastatic Castration-Resistant Prostate Cancer

By End-User * Hospitals

• Specialty Clinics
• Others

By Region * North America (By Radioisotopes, Type, End-User, and Country)

U.S.

Canada

• Europe (By Radioisotopes, Type, End-User, and Country/Sub-region)

Germany

U.K.

France

Spain

Italy

Rest of Europe

• Asia Pacific (By Radioisotopes, Type, End-User, and Country/Sub-region)

China

Japan

India

Australia

Rest of Asia Pacific

• Rest of the World (By Radioisotopes, Type, and End-User)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2024
• 4.2. Pipeline Analysis, by Key Players
• 4.3. Overview of Alternative Therapies
• 4.4. New Product Launches, by Key Players
• 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.6. Impact of COVID-19 on the Market

5. Global Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Radioisotope
  • 5.1.1. Radium-223
  • 5.1.2. Lutetium-177
  • 5.1.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Type
  • 5.2.1. Metastatic Castration-Resistant Prostate Cancer
  • 5.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
• 5.3. Market Analysis, Insights and Forecast - By End-user
  • 5.3.1. Hospitals
  • 5.3.2. Specialty Clinics
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Rest of the World

6. North America Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Radioisotope
  • 6.1.1. Radium-223
  • 6.1.2. Lutetium-177
  • 6.1.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Type
  • 6.2.1. Metastatic Castration-Resistant Prostate Cancer
  • 6.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
• 6.3. Market Analysis, Insights and Forecast - By End-user
  • 6.3.1. Hospitals
  • 6.3.2. Specialty Clinics
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Radioisotope
  • 7.1.1. Radium-223
  • 7.1.2. Lutetium-177
  • 7.1.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Type
  • 7.2.1. Metastatic Castration-Resistant Prostate Cancer
  • 7.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
• 7.3. Market Analysis, Insights and Forecast - By End-user
  • 7.3.1. Hospitals
  • 7.3.2. Specialty Clinics
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.4.1. Germany
  • 7.4.2. U.K.
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Radioisotope
  • 8.1.1. Radium-223
  • 8.1.2. Lutetium-177
  • 8.1.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Type
  • 8.2.1. Metastatic Castration-Resistant Prostate Cancer
  • 8.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
• 8.3. Market Analysis, Insights and Forecast - By End-user
  • 8.3.1. Hospitals
  • 8.3.2. Specialty Clinics
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Rest of the World Prostate Cancer Radiation Therapeutics Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Radioisotope
  • 9.1.1. Radium-223
  • 9.1.2. Lutetium-177
  • 9.1.3. Others
• 9.2. Market Analysis, Insights and Forecast - By Type
  • 9.2.1. Metastatic Castration-Resistant Prostate Cancer
  • 9.2.2. Non-Metastatic Castration-Resistant Prostate Cancer
• 9.3. Market Analysis, Insights and Forecast - By End-user
  • 9.3.1. Hospitals
  • 9.3.2. Specialty Clinics
  • 9.3.3. Others

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2024)
• 10.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
  • 10.2.1. Novartis AG
  • 10.2.2. Bayer AG
  • 10.2.3. Telix Pharmaceuticals Limited
  • 10.2.4. Ariceum Therapeutics
  • 10.2.5. Radiopharm Theranostics Limited
  • 10.2.6. Lantheus Holdings, Inc.
  • 10.2.7. Clarity Pharmaceuticals